Медикаментозное сопровождение адаптации к нарушениям рефракции с возрастом

Цель работы: оценка эффективности лечения препаратом «Оптинол» в отношении состояния глазной поверхности у лиц старше 35 лет с нарушением рефракции. Пациенты и методы. Исследование проводили в двух клинических группах и в группе контроля. Первая группа включала 74 пациента (148 глаз) с миопией средней степени (1а подгруппа) и высокой степени (1b подгруппа), средний возраст 38,3 ± 0,4 года. Вторую группу составили 49 пациентов (98 глаз) с гиперметропией средней степени (2а подгруппа) и высокой степени (2b подгруппа), средний возраст 42,3 ± 0,5 года. В группе контроля обследовано 25 здоровых лиц (50 глаз), средний возраст 38,2 ± 1,4 года. Анамнез пациентов, жалобы и сопутствующие заболевания оценивали методом анкетирования. Заключение. Результаты исследования доказали влияние гиперметропии средней и высокой степени на вероятность возникновения синдрома сухого глаза (ССГ).

1. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res. 2019 Jan;68:124–143. doi: 10.1016/j.preteyeres.2018.09.004.

2. Mai ELC, Lin CC, Lian I, Liao R, Chen M, Chang C. Population-based study on the epidemiology of dry eye disease and its association with presbyopia and other risk factors. Int Ophthalmol. 2019 Dec;39(12):2731–2739. doi: 10.1007/s10792-01901117-5.

3. Yılmaz OF, Alagöz N, Pekel G, Azman E, Aksoy EF, Cakır H, Bozkurt E, Demirok A. Intracorneal inlay to correct presbyopia: Long-term results. J Cataract Refract Surg. 2011 Jul;37(7):1275–1281. doi: 10.1016/j.jcrs.2011.01.027.

4. Бржевский В.В. Современные препараты «Искусственной слезы» в лечении больных с синдромом «Сухого глаза». Медицинский совет. 2013;2(2):42–49.

5. Zeev MS, Miller DD, Latkany R. Diagnosis of dry eye disease and emerging tech‑ nologies. Clin Ophthalmol. 2014 Mar 20;8:581–590. doi: 10.2147/OPTH.S45444.

6. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009 Jun;127(6):763–768. doi: 10.1001/archophthalmol.2009.103.

7. Sullivan DA. Tearful relationships? Sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. Ocul Surf. 2004 Apr;2(2):92–123. doi: 10.1016/s15420124(12)70147-7.

8. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000 Sep;118(9):1264–1268. doi: 10.1001/archopht.118.9.1264.

9. Yu EY, Leung A, Rao S, Lam DS. Effect of laser in situ keratomileusis on tear stability. Ophthalmology. 2000 Dec;107(12):2131–2135. doi: 10.1016/s0161-6420(00)00388-2.

10. Koh S, Maeda N, Ikeda C, Asonuma S, Ogawa M, Hiraoka T, Oshika T, Nishida K. The Effect of Ocular Surface Regularity on Contrast Sensitivity and Straylight in Dry Eye. Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2647–2651. doi: 10.1167/iovs.17-21894.

11. Schein OD, Muñoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997 Dec;124(6):723–728. doi: 10.1016/s0002-9394(14)71688-5.

12. Lafosse E, Wolffsohn JS, Talens-Estarelles C, García-Lázaro S. Presbyopia and the aging eye: Existing refractive approaches and their potential impact on dry eye signs and symptoms. Cont Lens Anterior Eye. 2020 Apr;43(2):103–114. doi: 10.1016/j.clae.2019.08.005.

13. Nejima R, Miyata K, Tanabe T, Okamoto F, Hiraoka T, Kiuchi T, Oshika T. Corneal barrier function, tear film stability, and corneal sensation after photorefractive keratectomy and laser in situ keratomileusis. Am J Ophthalmol. 2005 Jan;139(1):64–71. doi: 10.1016/j.ajo.2004.08.039.

14. Lee JB, Ryu CH, Kim J, Kim EK, Kim HB. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg. 2000 Sep;26(9):1326–1331. doi: 10.1016/s0886-3350(00)00566-6.

15. Grzybowski A, Gawęcki M. Presbyopia: What We Do Know and What We Do Not Know in 2022. J Clin Med. 2023 Jan 19;12(3):794. doi: 10.3390/jcm12030794.

16. Duane A. Studies in Monocular and Binocular Accommodation, with Their Clinical Application. Trans Am Ophthalmol Soc. 1922;20:132–157.

17. Pоinter JS. The presbyоpic аdd. II. Аge-relаted trend аnd а gender difference. Оphthаlmic Physiоl Оpt. 1995;15(4):241–248.

18. Nirmalan PK, Krishnaiah S, Shamanna BR, Rao GN, Thomas R. A population-based assessment of presbyopia in the state of Andhra Pradesh, south India: the Andhra Pradesh Eye Disease Study. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2324–2328. doi: 10.1167/iovs.05-1192.

19. Hickenbotham A, Roorda A, Steinmaus C, Glasser A. Meta-analysis of sex differences in presbyopia. Invest Ophthalmol Vis Sci. 2012 May 31;53(6):3215–3220. doi: 10.1167/iovs.12-9791.

20. Frick KD, Joy SM, Wilson DA, Naidoo KS, Holden BA. The Global Burden of Potential Productivity Loss from Uncorrected Presbyopia. Ophthalmology. 2015 Aug;122(8):1706–1710. doi: 10.1016/j.ophtha.2015.04.014.

21. Deschamps N, Ricaud X, Rabut G, Labbé A, Baudouin C, Denoyer A. The impact of dry eye disease on visual performance while driving. Am J Ophthalmol. 2013 Jul;156(1):184–189.e3. doi: 10.1016/j.ajo.2013.02.019.

22. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007 Mar;143(3):409–415. doi: 10.1016/j.ajo.2006.11.060.

23. Zheng Y, Wu X, Lin X, Lin H. The Prevalence of Depression and Depressive Symptoms among Eye Disease Patients: A Systematic Review and Meta-analysis. Sci Rep. 2017 Apr 12;7:46453. doi: 10.1038/srep46453.

24. Barabino S, Labetoulle M, Rolando M, Messmer EM. Understanding Symptoms and Quality of Life in Patients With Dry Eye Syndrome. Ocul Surf. 2016 Jul;14(3):365– 376. doi: 10.1016/j.jtos.2016.04.005.

25. Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, Varu DM, Musch DC, Dunn SP, Mah FS; American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology. 2019 Jan;126(1):P286–P334. doi: 10.1016/j.ophtha.2018.10.023.

26. Seitz B, Grüterich M, Cursiefen C, Kruse FE. Konservative und chirurgische Therapie der neurotrophen Keratopathie [Conservative and surgical treatment of neurotrophic keratopathy]. Ophthalmologe. 2005 Jan;102(1):15–26. German. doi: 10.1007/s00347-004-1161-7.

27. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000 Sep;118(9):1264–1258. doi: 10.1001/archopht.118.9.1264.

28. Ozdemir M, Temizdemir H. Age- and gender-related tear function changes in normal population. Eye (Lond). 2010 Jan;24(1):79–83. doi: 10.1038/eye.2009.21.

29. Fogt JS, Kowalski MJ, King-Smith PE, Epitropolous AT, Hendershot AJ, Lembach C, Maszczak JP, Jones-Jordan LA, Barr JT. Tear lipid layer thickness with eye drops in meibomian gland dysfunction. Clin Ophthalmol. 2016 Nov 7;10:2237–2243. doi: 10.2147/OPTH.S120158.

30. Al Tawil L, Aldokhayel S, Zeitouni L, Qadoumi T, Hussein S, Ahamed SS. Prevalence of self-reported computer vision syndrome symptoms and its associated factors among university students. Eur J Ophthalmol. 2020 Jan;30(1):189–195. doi: 10.1177/1120672118815110.

31. Mencucci R, Favuzza E, Decandia G, Cennamo M, Giansanti F. Hyaluronic Acid/ Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study. J Clin Med. 2021 Oct 13;10(20):4699. doi: 10.3390/jcm10204699.

32. Pflugfelder SC. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011 Dec;152(6):900–909.e1. doi: 10.1016/j.ajo.2011.08.023.